Evaluation of laboratory parameters of inflammation and oxidative stress in 95 control subjects and in 91 patients with epithelial ovarian cancer according to stage
Parameters . | Control subjects . | Stages I-II, n = 25 . | Stages III-IV, n = 66 . | P* . |
|---|---|---|---|---|
| CRP, mg/L | 2.6 ± 2.0 | 2.7 ± 1.9 | 29.0 ± 15.2† | < .001 |
| Fibrinogen, mg/dL | 345.0 ± 80.5 | 355.7 ± 62.5 | 523.5 ± 132.4† | < .001 |
| IL-1β, pg/mL | 13.0 ± 5.1 | 14.0 ± 5.1 | 26.7 ± 19.4† | .007 |
| IL-6, pg/mL | 1 ± 2.5 | 8.7 ± 5.6§ | 32.8 ± 23.2† | < .001 |
| TNFα, pg/mL | 19 ± 6.7 | 21.6 ± 7.7 | 39.4 ± 21.4† | .003 |
| Leptin, ng/mL | 19 ± 16.1 | 14.6 ± 9.8 | 7.1 ± 6.3† | .009 |
| ROS, Fort U | 197.5 ± 56.7 | 270.7 ± 39.5§ | 431.4 ± 69.5† | < .001 |
| GPx, U/L | 10 344.3 ± 2280.3 | 9984 ± 1563.0 | 6560.6 ± 2226.6† | < .001 |
| SOD, U/mL | 89.5 ± 18.4 | 80.6 ± 29.4 | 69.3 ± 32.9† | .028 |
Parameters . | Control subjects . | Stages I-II, n = 25 . | Stages III-IV, n = 66 . | P* . |
|---|---|---|---|---|
| CRP, mg/L | 2.6 ± 2.0 | 2.7 ± 1.9 | 29.0 ± 15.2† | < .001 |
| Fibrinogen, mg/dL | 345.0 ± 80.5 | 355.7 ± 62.5 | 523.5 ± 132.4† | < .001 |
| IL-1β, pg/mL | 13.0 ± 5.1 | 14.0 ± 5.1 | 26.7 ± 19.4† | .007 |
| IL-6, pg/mL | 1 ± 2.5 | 8.7 ± 5.6§ | 32.8 ± 23.2† | < .001 |
| TNFα, pg/mL | 19 ± 6.7 | 21.6 ± 7.7 | 39.4 ± 21.4† | .003 |
| Leptin, ng/mL | 19 ± 16.1 | 14.6 ± 9.8 | 7.1 ± 6.3† | .009 |
| ROS, Fort U | 197.5 ± 56.7 | 270.7 ± 39.5§ | 431.4 ± 69.5† | < .001 |
| GPx, U/L | 10 344.3 ± 2280.3 | 9984 ± 1563.0 | 6560.6 ± 2226.6† | < .001 |
| SOD, U/mL | 89.5 ± 18.4 | 80.6 ± 29.4 | 69.3 ± 32.9† | .028 |
Data are reported as mean ± standard deviation (SD). CRP indicates C-reactive protein; IL, interleukin; TNFα, tumor necrosis factor α; ROS, reactive oxygen species; GPx, glutathione peroxidase; SOD, superoxide dismutase.
P value was calculated with Student t test (patients with stages III-IV vs patients with stages I-II)
P < .05 in comparison to control subjects